• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pembrolizumab-induced bullous pemphigoid.

作者信息

Sun Christina W, Grossman Shoshana K, Aphale Abhishek, Hsu Sylvia

机构信息

Department of Dermatology, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania.

Fox Chase Cancer Center, Temple University Health System, Philadelphia, Pennsylvania.

出版信息

JAAD Case Rep. 2019 Apr 5;5(4):362-364. doi: 10.1016/j.jdcr.2019.02.008. eCollection 2019 Apr.

DOI:10.1016/j.jdcr.2019.02.008
PMID:31008169
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6453921/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e88/6453921/99ba613b37ec/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e88/6453921/5dbc13e1877f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e88/6453921/99ba613b37ec/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e88/6453921/5dbc13e1877f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e88/6453921/99ba613b37ec/gr2.jpg

相似文献

1
Pembrolizumab-induced bullous pemphigoid.帕博利珠单抗诱发的大疱性类天疱疮。
JAAD Case Rep. 2019 Apr 5;5(4):362-364. doi: 10.1016/j.jdcr.2019.02.008. eCollection 2019 Apr.
2
Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature.黏膜类天疱疮、大疱性类天疱疮与抗程序性死亡蛋白1/程序性死亡配体1：1例老年女性在帕博利珠单抗治疗转移性黑色素瘤后发生黏膜类天疱疮的病例报告及文献复习
Front Med (Lausanne). 2018 Sep 27;5:268. doi: 10.3389/fmed.2018.00268. eCollection 2018.
3
Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.PD-1 抑制剂不良事件报告系统中与 PD-1 抑制剂相关的大疱性类天疱疮不良事件的比例分析。
Expert Opin Drug Saf. 2019 Jul;18(7):623-633. doi: 10.1080/14740338.2019.1619693. Epub 2019 May 22.
4
Development of bullous pemphigoid during nivolumab therapy.纳武单抗治疗期间大疱性类天疱疮的发生
JAAD Case Rep. 2016 Dec 3;2(6):442-444. doi: 10.1016/j.jdcr.2016.05.009. eCollection 2016 Nov.
5
Bullous Pemphigoid as an Adverse Reaction to Pembrolizumab: Two Case Reports.大疱性类天疱疮作为帕博利珠单抗的不良反应：两例报告
Case Rep Dermatol. 2018 Jun 5;10(2):154-157. doi: 10.1159/000489661. eCollection 2018 May-Aug.
6
Bullous pemphigoid secondary to pembrolizumab mimicking toxic epidermal necrolysis.帕博利珠单抗继发大疱性类天疱疮，酷似中毒性表皮坏死松解症。
JAAD Case Rep. 2020 Apr 29;6(5):400-402. doi: 10.1016/j.jdcr.2020.03.003. eCollection 2020 May.
7
Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression.与帕博利珠单抗治疗转移性黑色素瘤并完全缓解相关的严重大疱性类天疱疮
Clin Exp Dermatol. 2017 Apr;42(3):309-312. doi: 10.1111/ced.13042. Epub 2017 Feb 16.
8
Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.一名接受派姆单抗治疗转移性黑色素瘤的患者出现迟发性泛发性类大疱性类天疱疮样反应。
Australas J Dermatol. 2017 Aug;58(3):e109-e112. doi: 10.1111/ajd.12488. Epub 2016 May 11.
9
Nonbullous pemphigoid secondary to PD-1 inhibition.PD-1抑制继发的非大疱性类天疱疮
JAAD Case Rep. 2019 Oct 3;5(10):898-903. doi: 10.1016/j.jdcr.2019.07.015. eCollection 2019 Oct.
10
Pembrolizumab-induced rash in a patient with angiosarcoma.帕博利珠单抗诱发血管肉瘤患者出现皮疹。
JAAD Case Rep. 2022 Aug 27;29:21-24. doi: 10.1016/j.jdcr.2022.08.030. eCollection 2022 Nov.

引用本文的文献

1
Steroid resistant bullous pemphigoid induced by pembrolizumab in a patient with metastatic lung adenocarcinoma: case report and review of the literature.帕博利珠单抗诱发的转移性肺腺癌患者类固醇抵抗性大疱性类天疱疮：病例报告及文献复习
Discov Oncol. 2025 Jul 1;16(1):1195. doi: 10.1007/s12672-025-02377-7.
2
Atypical Presentation of Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) in a Patient on Pembrolizumab: A Case Report.帕博利珠单抗治疗患者出现药物超敏反应伴嗜酸性粒细胞增多和全身症状（DRESS）的非典型表现：一例报告
Cureus. 2024 May 7;16(5):e59804. doi: 10.7759/cureus.59804. eCollection 2024 May.
3
Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid.

本文引用的文献

1
Bullous Pemphigoid as an Adverse Reaction to Pembrolizumab: Two Case Reports.大疱性类天疱疮作为帕博利珠单抗的不良反应：两例报告
Case Rep Dermatol. 2018 Jun 5;10(2):154-157. doi: 10.1159/000489661. eCollection 2018 May-Aug.
2
A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors.PD-1 和 PD-L1 抑制剂相关大疱性类天疱疮的研究综述。
Int J Dermatol. 2018 Jun;57(6):664-669. doi: 10.1111/ijd.13984. Epub 2018 Apr 6.
3
Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression.
帕博利珠单抗诱导的大疱性类天疱疮临床特征分析
Front Oncol. 2023 Mar 3;13:1095694. doi: 10.3389/fonc.2023.1095694. eCollection 2023.
4
Bullous Pemphigoid in Patients Receiving Immune-Checkpoint Inhibitors and Psoriatic Patients-Focus on Clinical and Histopathological Variation.接受免疫检查点抑制剂治疗的患者及银屑病患者中的大疱性类天疱疮——聚焦于临床和组织病理学变异
Dermatopathology (Basel). 2022 Mar 18;9(1):60-81. doi: 10.3390/dermatopathology9010010.
5
Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers.回顾性分析来自德国六个皮肤科中心的与检查点抑制剂治疗相关的大疱性类天疱疮病例。
Front Immunol. 2021 Feb 23;11:588582. doi: 10.3389/fimmu.2020.588582. eCollection 2020.
6
Bullous pemphigoid secondary to pembrolizumab mimicking toxic epidermal necrolysis.帕博利珠单抗继发大疱性类天疱疮，酷似中毒性表皮坏死松解症。
JAAD Case Rep. 2020 Apr 29;6(5):400-402. doi: 10.1016/j.jdcr.2020.03.003. eCollection 2020 May.
与帕博利珠单抗治疗转移性黑色素瘤并完全缓解相关的严重大疱性类天疱疮
Clin Exp Dermatol. 2017 Apr;42(3):309-312. doi: 10.1111/ced.13042. Epub 2017 Feb 16.
4
Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.抗程序性细胞死亡（PD）-1 治疗转移性黑色素瘤患者的皮肤不良事件（AE）：单机构队列。
J Am Acad Dermatol. 2016 Mar;74(3):455-61.e1. doi: 10.1016/j.jaad.2015.10.029. Epub 2016 Jan 12.
5
Immune checkpoint inhibitors: therapeutic advances in melanoma.免疫检查点抑制剂：黑色素瘤的治疗进展
Ann Transl Med. 2015 Oct;3(18):267. doi: 10.3978/j.issn.2305-5839.2015.10.27.
6
Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1.由免疫检查点抑制剂抗CTLA-4和抗PD-1引发的机会性自身免疫性疾病
Front Immunol. 2014 May 16;5:206. doi: 10.3389/fimmu.2014.00206. eCollection 2014.
7
Update on the pathogenesis of bullous pemphigoid: an autoantibody-mediated blistering disease targeting collagen XVII.大疱性类天疱疮发病机制的研究进展：一种针对 XVII 型胶原的自身抗体介导的水疱病。
J Dermatol Sci. 2014 Mar;73(3):179-86. doi: 10.1016/j.jdermsci.2013.12.001. Epub 2013 Dec 27.
8
Drug-induced pemphigoid: a review of the literature.药物性类天疱疮：文献综述
J Eur Acad Dermatol Venereol. 2014 Sep;28(9):1133-40. doi: 10.1111/jdv.12366. Epub 2014 Jan 10.
9
Antigen identification in drug-induced bullous pemphigoid.药物性大疱性类天疱疮中的抗原鉴定
J Am Acad Dermatol. 1993 Nov;29(5 Pt 2):879-82. doi: 10.1016/0190-9622(93)70262-r.